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Persistent and Safe Blood Pressure Lowering Effects of Renal Artery
Denervation: Three Year Follow-up From the Symplicity HTN-2 Trial
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Michael Bohm5
1Baker IDI Heart and Diabetes Institute, Melbourne, Australia, 2Monash University,
Melbourne, Australia, 3Baker Heart and Diabetes Institute, Melbourne, Australia,
4University Hospital Erlangen-Nürnberg, Erlangen , Germany, 5Universitätsklinikum
des Saarlandes, Homburg, Saarland
Background: The Symplicity HTN-2 trial randomized subjects with treatment-
resistant hypertension to renal artery denervation (RDN) with the Symplicity renal
denervation system or no RDN while all subjects were maintained on a consistent
antihypertensive drug regimen (3 drugs including a diuretic). The 6 month primary
endpoint demonstrated a signiﬁcant reduction in blood pressure (BP) in the RDN
group with no change in the control group. Long-term follow-up is now ongoing to
conﬁrm the safety and sustained beneﬁt of RDN.
Methods: Following the 6 month primary endpoint control subjects were eligible to
crossover to RDN. All subjects will be followed for 3 years (30 months post-RDN for
crossover patients) to assess long-term effectiveness and safety of RDN.
Results: At baseline, 60% of crossover subjects were female and 35% of RDN
subjects were female; 30 % of the crossover subjects and 40% of the RDN subjects
had type 2 diabetes. BP was signiﬁcantly lower than baseline at each time point
(table). At 2 years post-RDN 70% of subjects had a systolic BP drop of 20 mm Hg.
Medication changes were not associated with changes in BP. The heart rate drop
observed after RDN may be due to central sympathetic inhibition from afferent nerve
ablation. Bradycardia requiring atropine occurred during RDN in 13% of subjects with
no sequelae. There was 1 case of transient acute renal failure and 2 deaths unrelated to
RDN at 2 years.Ofﬁce BP
(mm Hg) Initial RDN
Cross-over to
RDN
Heart Rate
(bpm) Initial RDN
Cross-over to
RDN
Pre-procedure
baseliney
(n¼52) (n¼37) Pre-procedure
baseliney
(n¼52) (n¼37)
Systolic BP 178.217.7 190.919.6 74.7  14.9 71.8  15.3
Diastolic BP 97.015.8 101.416.2
6 mo. D from
baseline
(n¼49) (n¼35) 6 mo. D from
baseline
(n¼49) (n¼35)
Systolic BP -31.7  23.1 -23.7  27.5 -4.9  10.2 -2.6  13.9
Diastolic BP -11.7  11.2 -8.4  12.1 p<0.01 P¼0.28
12 mo. D from
baseline
(n¼47) (n¼33) 12 mo. D from
baseline
(n¼47) (n¼33)
Systolic BP -28.1  24.9 -23.8  30.5 -5.0  9.0 -6.4  13.1
Diastolic BP -9.7  10.6 -9.99  12.4 p<0.01 p<0.01
24 mo D from
baseline
Systolic
(n¼40) (n¼26) 24 mo D from
baseline
(n¼40) (n¼25)
BP -28.87  21.6 -35.3 30.5 -4.3  12.3 –0.1  11.6
Diastolic BP -10.4  11.2 -12.8  11.4 p¼0.03 P¼0.97
p<0.01for all BP changes from baseline
yCrossover group pre-procedure baseline is at 6 months post randomizationConclusions: RDN with the Symplicity catheter consistently reduced BP over 2
years with no serious safety concerns. Data to 3 years will be available for
presentation.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-59
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Background: Drug-resistant hypertension is a growing problem around the world.
Percutaneous sympathetic renal artery denervation is emerging as an approach for the
treatment of patients who do not respond adequately to optimal medical therapy.
Single-tip electrode radiofrequency ablation catheters have been used to achieve
sympathetic ﬁber interruption through the renal artery wall. However, long-term
results from systems designed to create predetermined stereotactic lesion pattern have
not been reported. We investigated the safety and efﬁcacy of a multi-electrode catheter
ablation system (EnligHTN) developed by St. Jude Medical.
Methods: The EnligHTN renal denervation system has 4 electrodes attached on
a basket mounted at the tip of the catheter. The basket is collapsed and can be
expanded via an external mechanism once the catheter is placed in the desired location
of the renal artery. The electrodes are then sequentially activated to achieve the desired
lesion pattern. The basket is then pulled back and repositioned for a new set of lesions
in order to optimize renal artery denervation. The EnligHTN-I ﬁrst-in-human study
was designed to assess the safety and efﬁcacy of this multi-electrode ablation system
in patients with drug-resistant hypertension.
Results: A total of 46 patients (average age 6010yrs taking an average of 4.10.6
medications) were enrolled in this study. Bilateral renal nerve ablation was performed.
Average reductions (mmHg) of ofﬁce BP at 1, 3, 6 and 12 months were -28/10, -27/
10, -26/10 and -27/11 mmHg (p<0.001). At 12 months there were no signiﬁcant
changes in the estimated glomerular ﬁltration rate (from 87 to 86 mL/min/1.73m2) or
in serum creatinine (from 78 to 80 mmol/L), but cystatin C levels improved (from 1.14
at baseline to 0.91 mg/L at 12 months, (p<0.0001)) in addition to improvements in
urine albumin-to-creatinine ratio (from 169 at baseline to 117 mg/g at 12 months
(p<0.0003)). Eighteen month efﬁcacy and safety data will be presented at the
meeting.
Conclusions: We conclude this data demonstrates that the EnligHTN ablation system
continues to be safe and effective in the treatment of patients with drug-resistant
hypertension.
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Background: The Symplicity renal denervation system was designed to deliver
low-power radio frequency energy within the renal artery to ablate the surrounding
nerves and thereby lower blood pressure (BP) in hypertensive patients unresponsive to
pharmacologic therapy. Controlled clinical trials have shown the renal denervation
(RDN) procedure to be safe and effective in patients with treatment-resistant hyper-
tension. The Global SYMPLICITY Registry (GSR) is designed to further evaluate the
safety and effectiveness of RDN with the Symplicity Flex catheter in real world
patients with hypertension.
Methods: The GSR is a prospective, multicenter, single-arm registry with an intended
enrollment of 5000 patients at w200 sites worldwide. Adult patients with diseases
characterized by an increased sympathetic activity are enrolled. Data collected
includes ofﬁce-based and ambulatory BP measurements, change in antihypertensive
medications, renal function measures, and protocol-deﬁned safety events.
Results: There were 617 patients treated as of January 2013. Baseline patient char-
acteristics include mean age of 6013 years, 63% males, and 38% have type 2 dia-
betes. The mean renal artery length was 4314 mm with a mean diameter of 5.71.3
mm. Baseline ofﬁce BP was 16423/8916 mmHg, mean estimated glomerular
ﬁltration rate was 8053 ml/min/1.73m2 and patients were taking 4.41.3 different
classes of antihypertensive drugs. There were no major procedural complications;
arterial spasm occurred in 9% of patients and 2 pseudoaneurysms occurred. In patients
with a baseline BP >160 mmHg (150 mmHg for patients with diabetes) the mean BP
drop was -1722/-713 mmHg at 3 months (n¼247) and -1720/-812 mmHg at 6
months (n¼134) (p<0.001 for both). No new reports of vascular abnormalities were
reported, There was 1 death, 2 myocardial infarctions, 2 hypertensive events requiring
hospitalization and 1 new end-stage renal disease.
Conclusions: Current data from the GSR demonstrates that RDN can be safety
applied in a real world population and signiﬁcant BP drops from baseline wereacts/ORAL/Renal Denervation and Endovascular Intervention B19
